The company plans to conduct several trials with its drug-device combo in schizophrenia and opioid use disorder over the next couple of years. by Urtė Fultinavičiūtė Delpor is sketching out late-stage clinical trial plans for [...]
Topline results of the Phase 1b/2a study were presented during a poster session at the 2023 Neuroscience Education Institute (NEI) Congress Delpor’s drug/device combination risperidone implant (DLP-114) was well tolerated for up to 12 months [...]
If approved, Delpor’s naltrexone implant is expected to offer a major advancement in the treatment of opioid use disorder by improving medication adherence and reducing relapses. BRISBANE, CA, April 19, 2022 — Delpor, Inc. (Delpor), [...]
Company expects to enter clinic by 2023 and if approved, Delpor’s tizanidine implant will be the first minimally invasive, long-acting therapy for the maintenance of moderate to severe spasticity Expanded pipeline supports long-term growth in [...]
If approved, Delpor’s risperidone implant will be the first once-yearly schizophrenia maintenance therapy. BRISBANE, CA, April 22, 2021 — Delpor, Inc. (Delpor), a clinical-stage biopharmaceutical company that utilizes innovative technologies in order to develop once-yearly [...]
Smith will also be responsible for optimizing customer experience for Delpor’s implant products, as he oversaw over 23k procedures for another implant biotech BRISBANE, CA, March 31, 2021 — Delpor, Inc. (Delpor), a clinical stage [...]
Company to expand the use of its PROZOR implant technology by building on the success with its lead antipsychotic program Upon successful completion of the grant’s initial phase, Delpor may receive additional funding in order [...]
The NIDDK continues to fund Delpor’s efforts to utilize its NANOPORTM technology in developing a matchstick-size subcutaneous implant device capable of delivering exenatide for 3-12 months through passive diffusion SAN FRANCISCO, CA, June 14, 2017 –Delpor, Inc. [...]
The patent covers Delpor’s PROZORTM technology which enables the sustained release of antipsychotics and other molecules from a matchstick-size implant device. Delpor has several products in development, including a 6-month formulation of risperidone, and a 3-month [...]
Delpor will be part of the Innovation Zone, a high profile 6,000 square foot exhibit space dedicated to showcasing 60 NIH and 20 NSF SBIR/STTR awardees. Delpor expects to meet with several potential partners interested [...]